Skip to Main Content

Paper Details

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
J Immunother Cancer
13
2023
Author NameAffiliation
Bradford J WoodCenter for Interventional Oncology, NIH Clinical Center & Center for Cancer Research, National Institutes of Health
Stephen M HewittCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Stephen M HewittCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Seth M SteinbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Seth M SteinbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Maggie CamNational Cancer Institute, National Institutes of Health
Tim F GretenCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Tim F GretenNational Cancer Institute, National Institutes of Health
  • 1 - 8

Datasets